iCAD, Inc. (Nasdaq:ICAD), an industry-leading provider of
advanced image analysis, workflow solutions and radiation therapy for
the early identification and treatment of cancer, today announced that
Company management will participate in the upcoming LD MICRO “Main
Event” Micro-Cap Growth Conference taking place from December 2-4, 2014
in Los Angeles. Ken Ferry, President and CEO of iCAD, Inc., will present
a corporate overview on Tuesday, December 2, 2014 at 12:30 p.m. PST
(3:30 p.m. EST).
Mr. Ferry’s presentation will be webcast live on the internet and can be
accessed at the Investors section of the Company’s website at www.icadmed.com,
where it will also be archived for 90 days.
About iCAD, Inc.
iCAD delivers innovative cancer detection and radiation therapy
solutions and services that enable clinicians to find and treat cancers
earlier and faster while enhancing patient care. iCAD offers a
comprehensive range of upgradeable computer aided detection (CAD) and
workflow solutions to support rapid and accurate detection of breast,
prostate and colorectal cancers. iCAD’s Xoft® Axxent® Electronic
Brachytherapy (eBx®) System® is a painless, non-invasive technology that
delivers high dose rate, low energy radiation, which targets cancer
while minimizing exposure to surrounding healthy tissue. The Xoft System
is FDA cleared and CE marked for use anywhere in the body, including
treatment of non-melanoma skin cancer, early-stage breast cancer and
gynecological cancers. The comprehensive iCAD technology platforms
include advanced hardware and software as well as management services
designed to support cancer detection and radiation therapy treatments.
For more information, visit www.icadmed.com
or www.xoftinc.com.
"Safe Harbor" Statement under the Private Securities Litigation
Reform Act of 1995
Certain statements contained in this News Release constitute
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. Such forward-looking
statements involve a number of known and unknown risks, uncertainties
and other factors which may cause the actual results, performance or
achievements of the Company to be materially different from any future
results, performance or achievements expressed or implied by such
forward-looking statements. Such factors include, but are not limited to
the Company’s ability to defend itself in litigation matters, to achieve
business and strategic objectives, the risks of uncertainty of patent
protection, the impact of supply and manufacturing constraints or
difficulties, uncertainty of future sales levels, protection of patents
and other proprietary rights, the impact of supply and manufacturing
constraints or difficulties, product market acceptance, possible
technological obsolescence of products, increased competition,
litigation and/or government regulation, changes in Medicare or other
reimbursement policies, risks relating to our existing and future debt
obligations, competitive factors, the effects of a decline in the
economy or markets served by the Company; and other risks detailed in
the Company’s filings with the Securities and Exchange Commission. The
words “believe”, “demonstrate”, “intend”, “expect”, “estimate”, “will”,
“continue”, “anticipate”, “likely”, “seek”, and similar expressions
identify forward-looking statements. Readers are cautioned not to place
undue reliance on those forward-looking statements, which speak only as
of the date the statement was made. The Company is under no obligation
to provide any updates to any information contained in this release. For
additional disclosure regarding these and other risks faced by iCAD,
please see the disclosure contained in our public filings with the
Securities and Exchange Commission, available on the Investors section
of our website at http://www.icadmed.com
and on the SEC’s website at http://www.sec.gov.
Copyright Business Wire 2014